Who this service is for
For management teams deciding whether and how to enter Israel, global regulatory teams aligning a local plan, and businesses needing a second opinion on a dossier, portfolio or operating model. The output is a decision-focused work plan with explicit assumptions.
Deliverables we can agree with you
- An overview of the current regulatory position, key uncertainties and information gaps.
- A comparison of feasible next steps and their dependencies, based on the information available.
- Regulatory input to launch planning, product prioritization or business-development due diligence.
- A phased work plan assigning responsibilities and identifying decisions needed before execution.
How the work progresses
Frame the decision
Define the business question, product scope, evidence available and the decisions your team needs to make.
Assess options
Examine readiness, local responsibilities and potential regulatory dependencies; distinguish confirmed facts from assumptions.
Set the next steps
Translate the assessment into a prioritized plan and agree whether follow-on implementation support is needed.
What to prepare for an initial conversation
Prepare a short product and company overview, existing approvals, the available dossier position, target activities in Israel and the decision you need to make. A useful consultation starts with a specific question rather than a generic request for approval speed.
Service scope
Regulatory strategy is one part of market entry. Commercial distribution, pricing, reimbursement and legal structuring may require separate specialists. The agreed scope makes those interfaces explicit and does not imply guaranteed authorization or market success.
Common questions
Can you provide a second opinion without taking over the work?
Yes. A focused review can examine a particular decision, dossier gap or proposed approach and provide findings for your existing team.
Can regulatory advice support a business-development decision?
Yes. Medicalix can assess regulatory readiness, open questions and likely workstreams within the agreed due-diligence scope. Commercial and financial assessments remain separate.
Can the engagement move from strategy to execution?
Yes. After agreeing the strategy and responsibilities, Medicalix can define a separate or continuing scope for registration, outsourcing, lifecycle work or local entity support.